ClinicalTrials.gg
CompletedNCT07787611Updated Aug 26, 2026

Phase I Clinical Study of MWN109 Tablets in Healthy Chinese Participants

A Phase 1 interventional study of MWN109 tablet and MWN109 tablet in Healthy Volunteers, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, Phase 1 clinical study conducted in China to evaluate the safety, tolerability, pharmacokinetic (PK), and the effect of meal timing following single and multiple oral doses of MWN109 tablets in Chinese participants.

The study consists of a single ascending dose (SAD) part and a multiple ascending dose (MAD) part. The SAD part includes 6 dose cohorts, with further evaluation of the effects of different meal-timing conditions at a selected dose level. The MAD part includes 4 dose cohorts administered with once-daily or every-other-day dosing regimens for up to 4 weeks.

Approximately 108 healthy participants aged 18 to 50 years are planned to be enrolled. The primary endpoint is safety, assessed by adverse events, serious adverse events, vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms. The secondary endpoint is the pharmacokinetic characteristics.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 50 years (inclusive at the time of signing the form).
  2. (BMI) = weight (kg) / height squared (m²): SAD part: 19.0 to 29.9 kg/m² (inclusive), with body weight ≥ 55 kg (male) or ≥ 50 kg (female); MAD part: 24.0 to 37.5 kg/m² (inclusive), with body weight ≥ 70 kg (male) or ≥ 60 kg (female).
  3. Resting heart rate/pulse ≥ 55 beats/min and ≤ 90 beats/min at screening and before randomization.

Exclusion criteria

Exclusion Criteria:

  1. History of severe drug allergy (especially known or suspected allergy to the of MWN109 tablets), severe atopic allergic disease/history (e.g., asthma, urticaria, eczematous dermatitis), or a severe allergic constitution.
  2. History of acute or chronic pancreatitis, symptomatic gallbladder disease, pancreatic injury, or other high-risk factors that may lead to pancreatitis, or amylase or lipase > 1.5 times the (ULN) at screening.
  3. Family history or history of medullary thyroid carcinoma; history of thyroid insufficiency or abnormal thyroid hormone levels.
  4. Gastrointestinal diseases present at screening that may increase participant risk, such as abnormal gastric emptying (e.g., gastroparesis, pyloric stenosis, pyloric obstruction) or severe chronic gastrointestinal diseases (e.g., history of intestinal obstruction, active ulcer within 6 months).
  5. History of infectious disease within 4 weeks prior to screening (which, in the investigator's judgment, may significantly affect the safety evaluation of the participant), or severe trauma or major surgery within 3 months.
  6. History of severe arrhythmia prior to screening judged by the investigator as unsuitable for participation in this study.
  7. Any of the following abnormal laboratory findings at screening: a) fasting blood glucose ≥ 7.0 mmol/L or \< 3.9 mmol/L, or > 6.5%; b) estimated (eGFR) \< 90 mL/min/1.73 m²; c) triglycerides (TG) ≥ 5.65 mmol/L.
  8. Blood donation, significant blood loss (> 400 mL), or receipt of blood transfusion within 3 months prior to screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    MWN109 Cohort A

    MWN109 Cohort A consists of 6 dose groups. In all dose groups, healthy participants are randomized to receive oral MWN109 tablets or placebo under fasted or fed conditions.

    Drug: MWN109 tablet · Drug: Placebo

  • Experimental
    MWN109 Cohort B

    MWN109 Cohort B consists of 4 dose groups. In all dose groups, healthy participants are randomized to receive oral MWN109 tablets or placebo once daily for a total of 4 weeks of treatment.

    Drug: MWN109 tablet · Drug: Placebo

Interventions

  • A1, A2, A3a, A3b, A3c, A4; administered orally

  • B1, B2, B3, B4; administered orally

  • DrugPlacebo

    administered orally

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    The incidence of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: From Day 1 to Day 42

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Cmax of MWN109 and its excipient, salcaprozate sodium (SNAC).

    Time frame: From Day 1 to Day 15

  2. Time to Reach Maximum Concentration (Tmax)

    Tmax of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 15

  3. Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)

    AUC0-t of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 15

  4. Area Under the Curve From Time 0 to Infinity (AUC0-inf)

    AUC0-inf of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 15

  5. Elimination Half-Life (t1/2)

    t1/2 of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 15

  6. Steady State Maximum Concentration (Cmax,ss)

    Cmax,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

  7. Steady State Minimum Concentration (Cmin,ss)

    Cmin,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

  8. Steady State Concentration (Cav,ss)

    Cav,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

  9. Time to Reach Maximum Concentration at Steady State (Tmax,ss)

    Tmax,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

  10. Steady State Apparent Terminal Elimination Half-life (t1/2,ss)

    t1/2,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

  11. Area Under Concentration-time Profiles during a Dose Interval (AUC0-τ,ss)

    AUC0-τ,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

  12. Steady State Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t,ss)

    AUC0-t,ss of MWN109 and its excipient, SNAC.

    Time frame: From Day 1 to Day 42

07

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)
    Kunming, Yunnan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Dec 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 26, 2026
StartActual
Jun 27, 2025
Primary completionActual
Dec 20, 2025
CompletionActual
Dec 20, 2025
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07787611
Responsible party
Sponsor
First posted
Aug 26, 2026
Start date
Jun 27, 2025
Primary completion
Dec 20, 2025
Completion
Dec 20, 2025
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MWN109

Start the discussion